Grossman H - Search Results

1

Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.

Hill A, Grossman H, Cohen C, Nadler J, Peeters M. Hill A, et al. Among authors: grossman h. HIV Clin Trials. 2007 Mar-Apr;8(2):68-76. doi: 10.1310/hct0802-68. HIV Clin Trials. 2007. PMID: 17507322 Clinical Trial.

2

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.

Cohen CJ, Berger DS, Blick G, Grossman HA, Jayaweera DT, Shalit P, Thompson M, Peeters M, de Béthune MP, Voorspoels E, Mack R, Woodfall B. Cohen CJ, et al. AIDS. 2009 Jan 28;23(3):423-6. doi: 10.1097/QAD.0b013e32831c5040. AIDS. 2009. PMID: 19114852 Clinical Trial.

3

Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.

Goldstein G, Conant MA, Beall G, Grossman HA, Galpin JE, Blick G, Calabrese LH, Hirsch RL, Fisher A, Stampone P, et al. Goldstein G, et al. Among authors: grossman ha. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):279-88. doi: 10.1097/00042560-199503010-00009. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7859140 Clinical Trial.

4

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; Nevirapine Toxicogenomics Study Team. Yuan J, et al. AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df. AIDS. 2011. PMID: 21505298 Free PMC article.

5

Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.

Grossman HA, Goon B, Bowers P, Leitz G; 010 Study Group. Grossman HA, et al. J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):368-78. doi: 10.1097/00126334-200312010-00003. J Acquir Immune Defic Syndr. 2003. PMID: 14615654 Clinical Trial.

6

HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.

Grossman H. Grossman H. AIDS Treat News. 2002 Sep 6;(383):2-7. AIDS Treat News. 2002. PMID: 12765126

7

Quality of life and HIV: current assessment tools and future directions for clinical practice.

Grossman HA, Sullivan PS, Wu AW. Grossman HA, et al. AIDS Read. 2003 Dec;13(12):583-90, 595-7. AIDS Read. 2003. PMID: 14959693 Review.

8

Addressing the need for HIV specialists: the AAHIVM perspective.

Grossman HA. Grossman HA. AIDS Read. 2006 Sep;16(9):479-86. AIDS Read. 2006. PMID: 17024767

9

Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H. Markowitz M, et al. Among authors: grossman h. J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. doi: 10.1097/QAI.0000000000001534. J Acquir Immune Defic Syndr. 2017. PMID: 29076941 Free PMC article. No abstract available.

10

Timing and T-cells.

Grossman HA. Grossman HA. Posit Aware. 2013 Mar-Apr;25(2):10-3. Posit Aware. 2013. PMID: 23646457 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

917 results

Search Page